Who this procedure is designed for

ChondroFiller® liquid is an injectable collagen scaffold, not a surgical intervention. A single outpatient appointment — no general anaesthetic, no incision — is all the procedure requires, and that distinction shapes who it is designed to help.

The primary indication is a focal articular cartilage defect in the knee: a discrete area of damage rather than widespread joint wear across the whole surface. Defects up to 6 cm² can be treated, and there is no upper age limit for the injectable pathway.

Four structured treatment tiers are used to match the injection to each patient's situation:

• Prevention — for early cartilage thinning where protecting existing tissue is the principal goal, before significant structural loss has occurred.
• Regeneration — for established focal defects where the scaffold's cell-recruiting properties are the primary aim: recruiting the patient's own progenitor cells to lay down new cartilage matrix.
• Combination — where ChondroFiller® is used alongside a second intra-articular therapy (such as a hydrogel or a biologic) to address different aspects of the joint environment simultaneously through distinct mechanisms.
• Support — for patients managing a broader pattern of joint change who need structural and symptomatic support rather than targeted focal repair alone.

A pre-consultation suitability assessment identifies the appropriate tier. For patients with large, unstable Grade III or IV lesions where direct surgical placement is preferable, an arthroscopic delivery route remains available — a clinician will advise which pathway fits.

How to prepare before the appointment

Preparation begins before the injection appointment is even confirmed. A clinical suitability assessment — covering your symptoms, relevant imaging, and the degree and location of cartilage change in the knee — takes place first. This conversation determines whether the injectable pathway is appropriate and, if so, which treatment tier fits your situation.

No hospital admission is involved. The entire attendance takes place in a clinic setting, with consultation, ultrasound assessment, and the injection all completed within a single visit. Because no general anaesthetic is used, standard pre-operative fasting rules do not apply.

On the practical side:

• Medications: Patients taking anticoagulants or blood-thinning medication should flag this when booking, as this may influence scheduling or pre-procedure planning. Any other specific medication questions should be raised with the clinic at the time of booking — do not stop or adjust prescribed medicines without clinical advice.
• What to bring: Any existing knee imaging (MRI, X-ray) is useful for the consultation.
• Referral: No GP referral is needed. Lincolnshire Knee accepts self-referral directly; appointments are available at Sleaford NG34 and Grantham NG31.

Patients should allow sufficient time for the full appointment rather than treating it as a brief clinic visit.

Step by step through the injection appointment

Once settled in the clinic room, the appointment moves through a clear sequence that most patients find reassuringly straightforward.

Reviewing the plan. The clinician begins by confirming the defect site, reviewing any available imaging, and discussing the treatment approach for that visit. This brief check ensures the correct volume of ChondroFiller® has been prepared — one box covers most focal defects; larger or multi-compartment lesions may call for two or three, a decision that will already have been discussed at the suitability stage.

Intravenous antibiotic cover. Before the injection itself, a short course of intravenous antibiotics is administered as a precaution. This is routine rather than a sign of complexity, and it adds minimal time to the visit.

Ultrasound preparation. The clinician applies an ultrasound probe to the knee, using real-time imaging to locate the cartilage defect precisely and to map the surrounding soft tissues and neurovascular structures. This is the same technology used for diagnostic knee ultrasound — there is no radiation involved. The live picture allows the clinician to see exactly where the needle needs to travel before it is introduced.

The injection. With the defect identified and the image guiding the needle in real time, the collagen solution is delivered through the needle directly into the defect. No incision is made. As the liquid ChondroFiller® contacts the joint environment, it begins to polymerise within minutes, setting into a stable gel that conforms to the shape of the defect and seats itself against the worn cartilage surface.

Leaving the same day. Once the injection is complete and any brief post-procedure checks are done, patients leave the clinic under their own power. There is no theatre recovery, no overnight stay, and no general anaesthetic to clear.

What the collagen scaffold does inside your knee

The gel that sets inside the defect has two distinct roles, and they unfold on very different timescales.

Immediate mechanical cushion. From the moment the collagen polymerises, it acts as a physical barrier between the worn cartilage surface and the opposing joint surface — an added layer that absorbs and distributes load where native cartilage has thinned. This effect is structural and begins within minutes of injection; it does not depend on any biological response from the surrounding tissue.

Scaffold for the body's own repair. Over the weeks and months that follow, the gel functions as a chemotactic matrix — drawing the patient's own mesenchymal progenitor cells from the surrounding cartilage, synovium, and subchondral bone into its structure. Once inside the scaffold, these cells differentiate and begin depositing cartilage-specific extracellular matrix. This process — acellular matrix-induced chondrogenesis — is driven entirely by the patient's own biology; the ChondroFiller® scaffold provides the structural framework and the chemical signals, not cells of its own.

As new tissue gradually forms, the collagen scaffold biodegrades. The full sequence unfolds over approximately six to twelve months, so any structural benefit builds progressively rather than appearing immediately after the appointment.

MRI provides an objective way to track this change. Published evidence reports reduced bone marrow oedema, less periarticular effusion, and visible widening of the joint space following treatment; MOCART cartilage regeneration scores of 70–87 have been reported across multiple international centres. These are population-level findings — individual outcomes depend on defect size, location, and the surrounding cartilage environment.

Recovery and what to expect in the weeks after

Because the injection requires no general anaesthetic and no surgical incision, there is no theatre recovery and no anaesthetic to clear before leaving. Patients walk out of the clinic under their own power — crutches are not routinely needed. Whether you can drive yourself home, and how much you should rest the knee in the first 24–48 hours, depends on individual factors your clinician will go through with you before you leave the appointment. It is worth arranging a lift for the day itself and planning for a quieter day or two while any mild post-injection tenderness settles.

The six-week follow-up

A follow-up appointment at six weeks is included in the London Cartilage Clinic package — the London arm of the MSK Doctors group — and allows the treating clinician to assess the knee and review early progress. Lincolnshire Knee, which operates under the same MSK Doctors group at sites in Sleaford and Grantham, may structure its follow-up pathway differently; confirm the specific arrangements at your pre-procedure consultation.

Monitoring progress over time

MRI is used in the published evidence base to confirm structural changes in the joint at appropriate review intervals; the MOCART scoring approach, outlined in the previous section, is the standard measure used in this evidence base. In published knee series, IKDC scores have improved by approximately 30 points at 12 months in suitable patients. These are population-level findings — individual outcomes depend on defect size, location, and the quality of the surrounding cartilage environment, not on any single person's result.

Costs, evidence gaps, and booking an assessment

Knowing the practical costs and the honest limits of the evidence tends to make the decision-making process clearer.

Funding and guide pricing

ChondroFiller® is self-funded private treatment — it is not currently available through the NHS and is not covered by private medical insurance. The London Cartilage Clinic (the London arm of the MSK Doctors group) publishes the following guide costs: £3,000, £5,500, and £8,000 depending on the volume of product required. Each package is inclusive — consultation, ultrasound imaging, the ChondroFiller® product itself, the injection, IV antibiotic cover, and the six-week follow-up appointment are all covered. Lincolnshire Knee-specific pricing should be confirmed directly at your assessment.

What the evidence shows — and where gaps remain

More than 19,000 cases have been performed globally, and the reported complication rate is approximately 0.06%, with reoperation rates in the range of 3–8% in published knee series. Those are reassuring figures. The honest caveat is that the bulk of the evidence comes from manufacturer-supported studies; independent randomised controlled trial data — particularly comparing the injectable route against viscosupplementation or PRP — are limited. Long-term durability beyond 24 months has not yet been fully established in the published literature.

Booking an assessment

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Consultations are available at Sleaford NG34 and Grantham NG31. Book an assessment at lincolnshireknee.co.uk.